-
1دورية أكاديمية
المؤلفون: Macarulla, Teresa, Hendifar, Andrew E, Li, Chung-Pin, Reni, Michele, Riess, Hanno, Tempero, Margaret A, Dueck, Amylou C, Botteman, Marc F, Deshpande, Chinmay G, Lucas, Eleanor J, Oh, Do-Youn
المصدر: Pancreas. 49(3)
مصطلحات موضوعية: Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Digestive Diseases, Pancreatic Cancer, Cancer, Clinical Research, Rare Diseases, 7.1 Individual care needs, Management of diseases and conditions, Good Health and Well Being, Aged, Chemotherapy, Adjuvant, Female, Health Status Indicators, Humans, Male, Middle Aged, Minimal Clinically Important Difference, Neoadjuvant Therapy, Neoplasm Staging, Pancreatectomy, Pancreatic Neoplasms, Patient Reported Outcome Measures, Predictive Value of Tests, Quality of Life, Time Factors, Treatment Outcome, health-related quality of life, minimally important difference, pancreatic cancer, pancreatic resection, patient-reported outcome measures, Clinical Sciences, Gastroenterology & Hepatology, Clinical sciences
وصف الملف: application/pdf
الوصول الحر: https://escholarship.org/uc/item/89q89333Test
-
2دورية أكاديمية
المؤلفون: Postma, Maarten J., Noone, Declan, Rozenbaum, Mark H., Carter, John A., Botteman, Marc F., Fenwick, Elisabeth, Garrison, Louis P.
المصدر: Postma , M J , Noone , D , Rozenbaum , M H , Carter , J A , Botteman , M F , Fenwick , E & Garrison , L P 2022 , ' Assessing the value of orphan drugs using conventional cost-effectiveness analysis : Is it fit for purpose? ' , Orphanet journal of rare diseases , vol. 17 , no. 1 , 157 . https://doi.org/10.1186/s13023-022-02283-zTest
مصطلحات موضوعية: Health equity, Orphan drug policy, Pharmaceutical policy, Rare diseases, Value of life, Value-based pricing
وصف الملف: application/pdf
الإتاحة: https://doi.org/10.1186/s13023-022-02283-zTest
https://hdl.handle.net/11370/dbc4a82a-1d26-44b1-ab98-1021ecdca3feTest
https://research.rug.nl/en/publications/dbc4a82a-1d26-44b1-ab98-1021ecdca3feTest
https://pure.rug.nl/ws/files/216918105/Assessing_the_value_of_orphan_drugs_using_conventional_cost_effectiveness_analysis_Is_it_fit_for_purpose_.pdfTest
http://www.scopus.com/inward/record.url?scp=85127594287&partnerID=8YFLogxKTest -
3دورية أكاديمية
المؤلفون: Postma, Maarten J., Noone, Declan, Rozenbaum, Mark H., Carter, John A., Botteman, Marc F., Fenwick, Elisabeth, Garrison, Louis P.
المصدر: Orphanet Journal of Rare Diseases; 4/5/2022, Vol. 17 Issue 1, p1-8, 8p
مصطلحات موضوعية: ORPHAN drugs, QUALITY-adjusted life years, COST effectiveness, DRUG utilization, RARE diseases